In the past years, both parties have successfully collaborated in technology transfer, product development and the advancement of clinical evidence in the field of Selective internal radiation therapy, referred to as SIRT (also known as Radioembolization, RA or Transarterial radioembolization, TARE) for the treatment of unresectable liver tumors.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
